Literature DB >> 8834829

Primary systemic allergy to human insulin: recurrence of generalized urticaria after successful desensitization.

H H Chng1, K P Leong, K C Loh.   

Abstract

Primary systemic allergy to human insulin is rare. We report a case of recurrent immediate local reactions followed eventually by generalized urticaria to recombinant human insulin (Humulin) in an insulin-dependent diabetic. Skin test to Humulin R was positive, and the patient was successfully desensitized using a modified rapid desensitization protocol. Two weeks later, he had another episode of generalized urticaria after Humulin R injection. His treatment was resumed at a lower dose, and within a week he was able to tolerate his usual regimen of insulin. To our knowledge, this is the first report of a recurrence of systemic reaction after successful desensitization.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8834829     DOI: 10.1111/j.1398-9995.1995.tb02512.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  4 in total

Review 1.  Allergic reactions to human insulin: a review of current knowledge and treatment options.

Authors:  Baris Akinci; Serkan Yener; Firat Bayraktar; Sena Yesil
Journal:  Endocrine       Date:  2009-10-30       Impact factor: 3.633

2.  Clinical applications of drug desensitization in the Asia-Pacific region.

Authors:  Bernard Yu-Hor Thong
Journal:  Asia Pac Allergy       Date:  2011-04-26

Review 3.  Insulin Allergy to Detemir Followed by Rapid Onset of Diabetic Ketoacidosis: A Case Report and Literature Review.

Authors:  Chong Boon Teo; Pek Yan Tan; Shan Xian Lee; Joan Khoo; Jun Guan Tan; Su Fen Ang; Sze Hwa Tan; Tunn Lin Tay; Eberta Tan; Su Chi Lim; Bernhard O Boehm; Wann Jia Loh
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-08       Impact factor: 5.555

4.  The complexities of insulin allergy: a case and approach.

Authors:  Babak Aberumand; Samira Jeimy
Journal:  Allergy Asthma Clin Immunol       Date:  2021-07-29       Impact factor: 3.406

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.